NASDAQ: URGN - UroGen Pharma Ltd.

छह महीने के लिए लाभप्रदता: -9.84%
भाग प्रतिफल: 0.00%
सेक्टर: Healthcare

पदोन्नति कार्यक्रम UroGen Pharma Ltd.

उन्नत शेड्यूल सरल ग्राफ
Financial Markets by TradingView

कंपनी के बारे में UroGen Pharma Ltd.

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer.

अधिक जानकारी
It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for NMIBC. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
तुलना सूची में जोड़ें
घड़ी सूची में जोड़ें
पोर्टफोलियो में जोड़ें
मूल्य सूचना जोड़ें

IPO date 2017-05-04
ISIN IL0011407140
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.urogen.com
Цена ао 11.52
प्रति दिन मूल्य परिवर्तन: 0% (11.45)
प्रति सप्ताह मूल्य परिवर्तन: -5.61% (12.13)
प्रति माह मूल्य परिवर्तन: +22.33% (9.36)
3 महीने में कीमत में बदलाव: +6.41% (10.76)
छह महीने में कीमत में बदलाव: -9.84% (12.7)
प्रति वर्ष मूल्य परिवर्तन: -23.67% (15)
3 वर्षों में मूल्य परिवर्तन: +31.76% (8.69)
5 वर्षों में मूल्य परिवर्तन: -59.12% (28.01)
वर्ष की शुरुआत से मूल्य परिवर्तन: +7.61% (10.64)
सभी पैरामीटर

बहुत मूल्यवान समझना

नाम अर्थ श्रेणी
P/S 4.99 3
P/BV -51.24 0
P/E 0 0
EV/EBITDA -4.16 0
कुल: 4.13

क्षमता

नाम अर्थ श्रेणी
ROA, % -54.68 0
ROE, % 342.83 10
कुल: 3.33

लाभांश

नाम अर्थ श्रेणी
Div yield, % 0 0
DSI 0 0
कुल: 0

कर्तव्य

नाम अर्थ श्रेणी
Debt/EBITDA -1.27 10
कुल: 7.8

विकास का आवेग

नाम अर्थ श्रेणी
लाभप्रदता Revenue, % 666.08 10
लाभप्रदता Ebitda, % -23.61 0
लाभप्रदता EPS, % -49.85 0
कुल: 2
अधिक जानकारी

संस्थानों आयतन शेयर करना, %
Great Point Partners LLC 2620545 8.49
Menora Mivtachim Holdings Ltd. 2303031 7.46
RA Capital Management, L.P. 1483697 4.81
Blackrock Inc. 1197647 3.88
Credit Suisse Ag/ 1060000 3.43
Harel Insurance Investments & Financial Services Ltd. 870194 2.82
RTW Investments LP 857464 2.78
Migdal Insurance & Financial Holdings Ltd. 648302 2.1
SILVERARC CAPITAL MANAGEMENT, LLC 508883 1.65
Wildcat Capital Management, LLC 495606 1.61

ETFशेयर करना, %वर्ष के लिए लाभप्रदता, %लाभांश, %
ARK Israel Innovative Technology ETF 1.67779 -2.68 1.21688
Amplify BlueStar Israel Technology ETF 0.57399 20.42 0.47569
iShares Micro-Cap ETF 0.12986 -13.97 1.54048
Future Tech ETF 0.05533 426.34 0.8416
Principal Healthcare Innovators ETF 0.05533 618.5 0.8416
Invesco Nasdaq Biotechnology ETF 0.04838 28.58 0.8565
ProShares Ultra Nasdaq Biotechnology 0.03147 51.7 0.85651
SPDR S&P International Small Cap ETF 0.03065 8.94 3.10348
Vanguard Russell 2000 Growth ETF 0.03 -10.8 0.60264
iShares Russell 2000 Growth ETF 0.02916 38.04 0.6026
Goldman Sachs ActiveBeta US Small Cap Equity ETF 0.02471 31.36 1.41955
Vanguard Russell 2000 ETF 0.02 -10.48 1.48801
ProShares UltraPro Russell2000 0.01005 89.82 1.47873
SPDR Portfolio Developed World ex-US ETF 0.00776 -4.91 3.28401
Fidelity MSCI Health Care Index ETF 0.00575 -4.29 1.46057
ProShares Hedge Replication ETF 0.00273 5.92 1.47892
iShares Russell 3000 ETF 0.00087 0.0303 1.43482
Vanguard Russell 3000 ETF 0 31.87 1.43817
0.1572.471.36



पर्यवेक्षक नौकरी का शीर्षक भुगतान जन्म का साल
Ms. Elizabeth A. Barrett President, CEO & Director 1.12M 1962 (63 वर्ष)
Mr. Dong Kim Chief Financial Officer 546.68k 1977 (48 साल)
Mr. Jason Drew Smith General Counsel, Chief Compliance Officer & Corporate Secretary 717.58k 1972 (53 वर्ष)
Vincent I. Perrone Senior Director of Investor Relations N/A
Mr. Bryon Wornson Executive Vice President of Talent, Advocacy & Communications N/A
Dr. Mark P. Schoenberg M.D. Chief Medical Officer 579.5k 1958 (67 साल)
Mr. James Ottinger R.ph. Executive Vice President of Regulatory Affairs & Quality N/A
Dr. Marina Konorty Ph.D. Executive Vice President of Research & Development and Technical Operations
Dr. Polly A. Murphy D.V.M., M.B.A., Ph.D. Chief Business Officer 1965 (60 साल)
Mr. Michael J. Louie M.D., M.P.H., M.Sc. Senior Vice President of Medical Affairs & Clinical Development

पता: United States, Princeton. NJ, 400 Alexander Park - Google मानचित्र में खोलें, यांडेक्स मानचित्र खोलें
वेबसाइट: https://www.urogen.com